Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings
By Dr. Matthew Watson
Basking Ridge, NJ, April 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber” or the "Company"), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that its Annual Meeting of Shareholders will be held at 1:00 pm EDT on Thursday, June 3, 2021 (the “Annual Meeting”). The Company has established April 12, 2021 as the record date for the Annual Meeting.
Related Post
- Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer’s Association International Conference - July 22nd, 2021
- NHS Surgeon First in Europe to Implant TELA Bio's OviTex® LPR Reinforced Tissue Matrix - July 22nd, 2021
- Vericel to Report Second-Quarter 2021 Financial Results on August 4, 2021 - July 22nd, 2021
- Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences’ CAReS Study on July 28, 2021 - July 22nd, 2021
- LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare... - July 22nd, 2021
- Tauriga Sciences Inc. Commences Sales of its Tauri-Gum Product Line in the United Kingdom - July 22nd, 2021
- Nanopharm and Leyden Labs Announce Agreement to Develop Intranasal Spray Product Candidates for Prophylactic Use Against Known and New Respiratory... - July 22nd, 2021
- Berkeley Lights announces technology collaboration to accelerate and improve gene therapy viral vector development and manufacturing - July 22nd, 2021
- Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board - July 22nd, 2021
- Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2... - July 22nd, 2021
- Spectral Medical Inc. Announces $10 Million Offering - July 22nd, 2021
- Medolife Rx Schedules Investor Webcast for Tuesday, July 27, 2021 - July 22nd, 2021
- Major Shareholder Announcement - July 22nd, 2021
- Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug... - July 22nd, 2021
- Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update - July 22nd, 2021
- ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients - July 22nd, 2021
- Kane Biotech Announces Cancellation of Options and Issuance of Restricted Share Units - July 22nd, 2021
- Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities - July 22nd, 2021
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results - July 22nd, 2021
- argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021 - July 22nd, 2021
- Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777 - July 7th, 2021
- Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer - July 7th, 2021
- Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference - July 7th, 2021
- Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China - July 7th, 2021
- Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology - July 7th, 2021
- CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors - July 7th, 2021
- Amazon Brand Registry Approves the Application for the Company’s Flagship Brand: Tauri-Gum - July 7th, 2021
- Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations - July 7th, 2021
- Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2021 - July 7th, 2021
- Integrity Implants and Fusion Robotics Merge to Form Accelus - July 7th, 2021
- AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET - July 7th, 2021
- Capital Increase in Genmab as a Result of Employee Warrant Exercise - July 7th, 2021
- FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients - July 7th, 2021
- Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel... - July 7th, 2021
- Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis - July 7th, 2021
- Auxly Strengthens Financial Position With the Implementation of Amendments to Imperial Brands $123 Million Convertible Debenture and Sale of Curative... - July 7th, 2021
- NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors - July 7th, 2021
- XBiotech Announces Dividend to Holders of Common Stock - July 7th, 2021
- Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles - July 7th, 2021
- Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021 - July 7th, 2021
- Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD - June 25th, 2021
- Starpharma to Webcast Live at Life Sciences Investor Forum June 24th - June 25th, 2021
- PAOG Targets $18 Billion Market Opportunity With New CBD Nutraceutical To Be Packaged By ALKM And Marketed By USMJ - June 25th, 2021
- Mountain Valley MD Provides Update on Key Strategic Initiatives: Patent Award, FDA Collaborative Research Agreement, Cold Chain, Dose Sparing,... - June 25th, 2021
- Axiom Presents "Unified Platforms: How to Address the Complexity of Oncology Studies to Better Support Your Sites" at Clinical Operations in... - June 25th, 2021
- Oculogica’s New Patent Opens Potential for a CTE Test for Live Subjects - June 25th, 2021
- Top liver disease conference showcases positive clinical data from Yaqrit’s technologies - June 25th, 2021
- OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting - June 25th, 2021
- Sorrento Receives EUA Approval and Import License From Mexico Authority COFEPRIS For COVI-STIX™ (COVID-19 Virus Rapid Antigen Detection Test) and... - June 25th, 2021
- Lowell Farms to Webcast Live at 2021 VirtualInvestorConferences.com on June 29 - June 25th, 2021
- Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201 - June 25th, 2021
- Adverum Announces Changes to Management Team - June 25th, 2021
- Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1 - June 25th, 2021
- Bioventus Invests in Vaporox - June 25th, 2021
- Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with... - June 25th, 2021
- Avicanna Announces Results of Annual General Meeting and Provides Corporate Update - June 25th, 2021
- Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149 - June 25th, 2021
- Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell... - June 25th, 2021
- Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates - June 25th, 2021
- Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes - June 25th, 2021
- BetterLife Closes $2.61 Million Marketed Public Offering - June 8th, 2021
- 22nd Century Advances Initiatives to Strengthen and Maximize Revenue Opportunities in Hemp/Cannabis Franchise - June 8th, 2021
- 22nd Century Announces $40 Million Common Stock Registered Direct Offering - June 8th, 2021
- Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2021 - June 8th, 2021
- Déclaration d’actions et de droits de vote de la société Valneva SE – Mai 2021 - June 8th, 2021
- FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease - June 8th, 2021
- Sanofi launches its new global employee share ownership plan - June 8th, 2021
- Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™ - June 8th, 2021
- Reata Pharmaceuticals Announces Participation in The Goldman Sachs 42nd Annual Global Healthcare Conference - June 8th, 2021
- Design Therapeutics Expands Board of Directors with Key Appointments - June 8th, 2021
- Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference - June 8th, 2021
- Centessa Pharmaceuticals to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference - June 8th, 2021
- Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven - June 8th, 2021
- HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+... - June 8th, 2021
- Zymergen to Present at Goldman Sachs Annual Global Healthcare Conference - June 8th, 2021
- Avicanna Provides Bi-Weekly Update On Status Of Management Cease Trade Order - June 8th, 2021
- Roche obtains CE mark for the SARS-CoV-2 Antigen Self Test Nasal allowing for rapid self testing of COVID-19 at home - June 8th, 2021
- Orion and the Blood Service launch collaboration to develop new CAR T-cell cancer therapy - June 8th, 2021
- Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need for Novel Therapies for Severe Infections and the Potential Role of... - June 8th, 2021
- OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME) - June 8th, 2021
Global News Feed
Comments Off on Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings |
April 4th, 2021
This author published 3912 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research